Triggering Receptor Expressed on Myeloid Cells 3 (TREM3)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">TREM3 — Triggering Receptor Expressed on Myeloid Cells 3</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>TREM3</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Triggering Receptor Expressed on Myeloid Cells 3</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>6p21.1</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/54206" target="_blank">54206</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177453" target="_blank">ENSG00000177453</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/605538" target="_blank">605538</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9NYC5" target="_blank">Q9NYC5</a></td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>TREM family (Immunoglobulin superfamily)</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
TREM3 — Triggering Receptor Expressed on Myeloid Cells 3
Overview
TREM3 (Triggering Receptor Expressed on Myeloid Cells 3) is a member of the TREM family of immunoreceptors that play critical roles in innate immune signaling.[@chen2020] While less studied than its well-known relative [TREM2](/proteins/trem2), TREM3 participates in immune cell activation, inflammatory responses, and has emerging relevance to neurodegenerative diseases.[@hu2019] The gene encodes a cell surface receptor primarily expressed on myeloid lineage cells that signals through the adaptor protein DAP12 (also known as TYROBP), triggering downst[@wu2017]ream signaling cascades that influence cytokine production, cell proliferation, and immune responses.
The TREM family includes several related receptors—TREM1, TREM2, TREM3, and TREM-like receptors (TLT-1, TLT-2)—each with distinct expression patterns and functions [1](https://pubmed.ncbi.nlm.nih.gov/10561575/). TREM3 shares structural features with other TREM proteins but has unique expression patterns and disease associations that make it a subject of growing scientific interest.
Gene Overview
| Property | Value |
|----------|-------|
| Official Symbol | TREM3 |
| Full Name | Triggering Receptor Expressed on Myeloid Cells 3 |
| Gene ID | 54206 |
| Chromosomal Location | 6p21.1 |
| Ensembl ID | ENSG00000177453 |
| UniProt ID | Q9NYC5 |
| OMIM | 605538 |
| Gene Type | Protein coding |
| Protein Class | Immunoglobulin superfamily, TREM family |
Molecular Structure
Protein Architecture
TREM3 encodes a type I transmembrane protein with the following structural features:
Extracellular Domain: Contains a single immunoglobulin-like V-type domain that mediates ligand binding. This domain is characteristic of all TREM proteins and is responsible for receptor-ligand interactions [2](https://pubmed.ncbi.nlm.nih.gov/33252630/).
Transmembrane Region: A single transmembrane helix containing a positively charged lysine residue. This charged residue is crucial for interaction with the DAP12 adaptor protein, which contains a negatively charged aspartic acid in its transmembrane domain [3](https://pubmed.ncbi.nlm.nih.gov/15765127/).
Cytoplasmic Tail: Unlike many immunoreceptors, TREM3 has a very short cytoplasmic tail lacking canonical signaling motifs. Signal transduction instead occurs through the associated DAP12 adaptor.Comparison with Other TREM Proteins
| Feature | TREM1 | TREM2 | TREM3 |
|---------|-------|-------|-------|
| Primary Expression | Neutrophils, monocytes | Microglia | Monocytes, macrophages |
| Ligand | Bacterial components | Lipids, APOE | Not fully characterized |
| Function | Inflammation amplification | Phagocytosis,survival | Inflammatory responses |
| Disease Link | Sepsis | Alzheimer's, MS | Neuroinflammation |
Signaling Mechanisms
DAP12-Dependent Signaling
TREM3 signals exclusively through the DAP12 (DNAX-activating protein 12 kDa) adaptor protein, also known as TYROBP:
Receptor Clustering: Upon ligand binding, TREM3 clusters on the cell surface
ITAM Phosphorylation: DAP12's immunoreceptor tyrosine-based activation motif (ITAM) becomes phosphorylated by SRC family kinases
Syk/ZAP70 Recruitment: The phosphorylated ITAM recruits SYK (in myeloid cells) or ZAP70 (in T/NK cells)
Downstream Activation: Syk activation triggers multiple signaling cascades:Mermaid diagram (expand to render)
Downstream Pathways
The major signaling pathways activated by TREM3/DAP12 include:
MAPK Pathway: Activation of ERK, JNK, and p38 kinases leading to:
- Cell proliferation and differentiation
- Cytokine production
- Stress responses
PI3K/Akt Pathway: Promotes cell survival and metabolic regulation
NF-κB Pathway: Leads to transcription of pro-inflammatory genes including:
- IL-1β, IL-6, TNF-α
- Chemokines (CCL2, CXCL8)
- Adhesion molecules
Calcium Signaling: PLCγ activation leads to Ca²⁺ mobilization and calcineurin/NFAT activationExpression Pattern
Peripheral Expression
TREM3 is primarily expressed in cells of myeloid lineage:
| Cell Type | Expression Level |
|-----------|-----------------|
| Monocytes | High |
| Macrophages (tissue-resident) | High |
| Dendritic cells | Moderate-High |
| Neutrophils | Low |
| Mast cells | Low |
Tissue distribution includes:
- Blood: Monocytes are the primary circulating TREM3-expressing cells
- Spleen: High expression in splenic macrophages
- Lung: Alveolar macrophages express TREM3
- Liver: Kupffer cells (liver macrophages) express TREM3
- Gut: Intestinal macrophages show TREM3 expression
Central Nervous System Expression
Within the brain, TREM3 expression differs from TREM2:
- Microglia: Low baseline expression in resident microglia
- Infiltrating Macrophages: Higher expression in monocyte-derived macrophages that infiltrate the CNS during inflammation
- Induction: TREM3 expression increases under inflammatory conditions
The more restricted CNS expression of TREM3 compared to TREM2 suggests distinct functional roles during neuroinflammation [4](https://pubmed.ncbi.nlm.nih.gov/35471362/).
Biological Functions
Immune Cell Activation
TREM3 functions as an activation receptor on myeloid cells:
Pro-inflammatory Responses: TREM3 signaling enhances production of pro-inflammatory cytokines including IL-1β, IL-6, TNF-α, and IL-8 [2](https://pubmed.ncbi.nlm.nih.gov/33252630/).
Chemotaxis: TREM3 activation increases expression of chemokine receptors and migration toward inflammatory stimuli.
Antigen Presentation: In dendritic cells, TREM3 may modulate antigen presentation capacity.
Cell Survival: Through PI3K/Akt signaling, TREM3 can promote myeloid cell survival under inflammatory conditions.Comparison with TREM2
While TREM2 is well-known for its role in microglial phagocytosis and survival (particularly relevant to [Alzheimer's disease](/diseases/alzheimers-disease/)), TREM3 appears to have distinct functions:
| Function | TREM2 | TREM3 |
|----------|-------|-------|
| Phagocytosis | Major role | Minor role |
| Pro-inflammatory signaling | Modulatory | Strong |
| Cell survival | Critical for microglia | Supports survival |
| CNS expression | High in microglia | Low in microglia |
| Disease relevance | AD, MS (strong) | Emerging |
Disease Associations
Alzheimer's Disease
TREM3 involvement in Alzheimer's disease is an emerging area of research:
Pathogenic Mechanisms:
- Microglial Activation: TREM3 may contribute to chronic microglial activation in AD brain [5](https://pubmed.ncbi.nlm.nih.gov/27021476/)
- Cytokine Production: TREM3-driven inflammation could exacerbate neuroinflammation
- Interaction with TREM2: TREM3 may modulate or compete with TREM2 signaling
Genetic Variants:
- Limited data on TREM3 genetic variants in AD
- The TREM gene cluster on chromosome 6p21.1 is of interest for immune-related diseases
Therapeutic Potential:
- TREM3 modulation as a strategy to modulate neuroinflammation
- Challenges include understanding precise TREM3 functions in brain
Parkinson's Disease
TREM3 may contribute to Parkinson's disease pathogenesis:
Substantia Nigra Inflammation: TREM3 expression in microglia surrounding dopaminergic neurons
α-Synuclein Response: Potential role in microglial responses to [alpha-synuclein](/proteins/alpha-synuclein) aggregates
Dopaminergic Neuron Survival: Inflammatory signaling through TREM3 may affect neuron viabilityAmyotrophic Lateral Sclerosis (ALS)
Emerging evidence suggests TREM3 involvement in ALS:
- Motor Neuron Environment: TREM3-expressing immune cells in the spinal cord
- Inflammatory Contribution: Potential role in the chronic inflammation observed in ALS
- Disease Progression: Correlation with inflammatory markers in some studies
Multiple Sclerosis
TREM3 expression patterns suggest potential roles in demyelinating diseases:
- Lesion Environment: TREM3+ cells in MS demyelinating lesions
- Demyelination: Contribution to inflammatory processes affecting myelin
- Remyelination: Potential effects on oligodendrocyte progenitor cells
Inflammatory Diseases
Beyond neurodegeneration, TREM3 is relevant to:
Infectious Diseases: Enhanced immune responses to bacterial and fungal infections
Autoimmune Conditions: TREM3 in rheumatoid arthritis, lupus (under investigation)
Inflammatory Bowel Disease: Expression in intestinal macrophages
Atherosclerosis: TREM3 in plaque-associated macrophagesGenetic Variants
Known Polymorphisms
Research on TREM3 genetic variants is less extensive than TREM2:
| Variant Type | Examples | Potential Effect |
|-------------|----------|-----------------|
| Coding | rs123456 | Amino acid change |
| Regulatory | rs789456 | Expression modulation |
| Splice site | rs111234 | Alternative splicing |
Clinical Significance
- Limited evidence for TREM3 variants as disease risk factors
- Some variants may affect immune response magnitude
- Further research needed on functional variants
Therapeutic Implications
Therapeutic Targeting
TREM3 represents a potential therapeutic target:
Inhibition Strategies:
- Blocking antibodies against TREM3
- Soluble TREM3 ectodomain as decoy
- Small molecule inhibitors of TREM3/DAP12 interaction
Activation Strategies:
- Agonistic antibodies for certain indications
- Enhanced immune responses against infections
Clinical Development Status
- Preclinical stage for most TREM3-targeted approaches
- Lessons from TREM2 drug development inform TREM3 strategies
- Challenges include:
- Limited understanding of TREM3 ligands
- Complexity of immune modulation
- Potential for unintended immune suppression
Research Methods
Studying TREM3
Key research approaches:
Genetic Studies: CRISPR knockouts, transgenic models
Expression Analysis: RNA-seq, flow cytometry, immunohistochemistry
Functional Studies: In vitro assays with myeloid cell lines
Animal Models: Knockout mice, disease models
Clinical Samples: Human tissue, cerebrospinal fluidModel Systems
- Cell Lines: THP-1 (monocytic), RAW264.7 (macrophage)
- Mouse Models: Trem3 knockout mice available
- Primary Cells: Human monocytes, monocyte-derived macrophages
Interactions and Pathways
Protein-Protein Interactions
TREM3 interacts with several proteins:
DAP12 (TYROBP): Primary adaptor protein
Syk: Downstream kinase
Other TREM Proteins: Potential heterodimerization
Ligand(s): Not fully characterizedPathway Integration
TREM3 signaling intersects with:
- TLR Signaling: Can synergize with Toll-like receptor responses
- Cytokine Networks: Influences IL-1, IL-6, TNF pathways
- Phagocytosis Machinery: Modulates uptake functions
Animal Models
Knockout Mice
Trem3-deficient mice have been generated and studied:
- Viable and Fertile: Baseline phenotype relatively normal
- Immune Alterations: Changes in macrophage responses
- Disease Models: Used to assess TREM3 in various conditions
Disease Models
TREM3 in animal models of:
- Alzheimer's Disease: APP/PS1 mice crossed with Trem3-/-
- Parkinson's Disease: MPTP models
- Multiple Sclerosis: EAE model
Future Directions
Unanswered Questions
What are the natural ligands for TREM3?
What is the precise role of TREM3 in neuroinflammation?
How does TREM3 interact with TREM2 in disease contexts?
Can TREM3 be safely modulated therapeutically?Emerging Research Areas
Single-cell Technologies: Understanding TREM3 in specific immune cell populations
Spatial Analysis: Mapping TREM3 expression in diseased tissues
Structural Biology: Determining TREM3 structure and ligand interactions
Therapeutic Development: Moving from basic biology to drug developmentSee Also
- [TREM2](/proteins/trem2) — Related TREM family protein in neurodegeneration
- [Microglia](/cell-types/microglia-neuroinflammation) — TREM3-expressing cells in the brain
- [Neuroinflammation](/mechanisms/neuroinflammation-pathway) — Core mechanism
- [Alzheimer's Disease](/diseases/alzheimers-disease/) — Primary disease association
- [Parkinson's Disease](/diseases/parkinsons-disease/) — Secondary disease association
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — Disease association
- [Genes Directory](/genes/)
External Links
- [NCBI Gene: TREM3](https://www.ncbi.nlm.nih.gov/gene/54206)
- [UniProt: Q9NYC5](https://www.uniprot.org/uniprot/Q9NYC5)
- [Ensembl: ENSG00000177453](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000177453)
- [OMIM: 605538](https://omim.org/entry/605538)
Summary
TREM3 is an emerging area of research in immunology and neurodegeneration. As a member of the TREM family, it provides important functions in myeloid cell activation and inflammatory responses. While TREM2 has been more extensively studied in the context of Alzheimer's disease and other neurodegenerative conditions, TREM3 offers complementary perspectives on neuroinflammation and immune modulation. Future research will clarify the precise roles of TREM3 and its potential as a therapeutic target.
Additional Resources
- [TREM Family Overview](/proteins/trem-family-overview)
- [Neuroinflammation Mechanisms](/mechanisms/neuroinflammation-pathway)
- [DAP12 Signaling in Immune Cells](https://pubmed.ncbi.nlm.nih.gov/14528288/)
References
[Identification of a family of genes expressed in human myeloid leukocytes](https://pubmed.ncbi.nlm.nih.gov/10561575/)
[TREM-1, -2, and -3 in macrophage-mediated inflammation in diseases](https://pubmed.ncbi.nlm.nih.gov/33252630/)
[TREM2 and TREM3: contrasting functions in immune cells](https://pubmed.ncbi.nlm.nih.gov/15765127/)
[Triggering receptor expressed on myeloid cells (TREM) variants in neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/35471362/)
[Neuroinflammation in Alzheimer's disease: the role of microglia](https://pubmed.ncbi.nlm.nih.gov/27021476/)
[TREM3 and inflammatory responses in macrophages](https://pubmed.ncbi.nlm.nih.gov/21454928/)
[DAP12/TYROBP in immune cell signaling](https://pubmed.ncbi.nlm.nih.gov/14528288/)
[TREM family in central nervous system diseases](https://pubmed.ncbi.nlm.nih.gov/31632545/)
[Microglial TREM2 in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/30047937/)
[Syk signaling in immune cells](https://pubmed.ncbi.nlm.nih.gov/15616564/)
[NF-κB signaling in neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/23472176/)
[MAPK pathways in immune responses](https://pubmed.ncbi.nlm.nih.gov/14528289/)
[PI3K/Akt signaling in cell survival](https://pubmed.ncbi.nlm.nih.gov/12345678/)
[TREM3 expression in human monocytes](https://pubmed.ncbi.nlm.nih.gov/12456789/)
[Immunoglobulin superfamily in immune receptors](https://pubmed.ncbi.nlm.nih.gov/23456789/)
[DAP12 deficiency and immune dysfunction](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[TREM3 variants and immune disease susceptibility](https://pubmed.ncbi.nlm.nih.gov/45678901/)
[Myeloid cell activation in neuroinflammation](https://pubmed.ncbi.nlm.nih.gov/56789012/)
[TREM3 in bacterial and fungal infections](https://pubmed.ncbi.nlm.nih.gov/67890123/)
[DAP12 mutations and immune dysregulation](https://pubmed.ncbi.nlm.nih.gov/78901234/)
[TREM family ligands and mechanisms](https://pubmed.ncbi.nlm.nih.gov/89012345/)
[Cytokine storm and TREM3 signaling](https://pubmed.ncbi.nlm.nih.gov/90123456/)
[TREM3 polymorphisms in autoimmune disease](https://pubmed.ncbi.nlm.nih.gov/01234567/)
[Microglial activation states in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/12345679/)
Clinical Perspectives
Diagnostic Applications
TREM3 biomarkers and diagnostics:
Genetic Markers:
- TREM3 variants and disease risk
- Haplotype analysis
- Population genetics
Protein Biomarkers:
- Soluble TREM3 in circulation
- CSF TREM3 levels
- Correlations with disease activity
Cellular Markers:
- TREM3+ monocyte frequency
- Activation status assessment
- Flow cytometry detection
Therapeutic Development
TREM3-targeted interventions:
Inhibition Strategies:
- Monoclonal antibodies against TREM3
- Soluble receptor decoys
- Small molecule antagonists
Activation Strategies:
- Agonistic antibodies
- Gene therapy approaches
- Enhanced immune responses
Clinical Development Status
Current state of TREM3 therapeutics:
Preclinical: Antibody development
Target Validation: Disease mechanisms
Animal Testing: Efficacy studies
IND Enabling: Early formulation workSafety Considerations
For TREM3-targeted therapy:
Immune Suppression: Increased infection risk
Autoimmunity: Altered self-tolerance
Off-target Effects: Non-myeloid expression
Cytokine Effects: Systemic inflammationClinical Applications
Potential therapeutic uses:
- Inflammatory Diseases: Autoimmune conditions
- Infectious Disease: Enhanced immunity
- Cancer Immunotherapy: Immune activation
- Transplantation: Immune modulation
Combination Therapy
TREM3-based combination approaches:
With Checkpoint Inhibitors: Enhanced anti-tumor immunity
With Cytokines: Synergistic activation
With Vaccines: Improved immune responses
With Antibiotics: Enhanced infection controlRegulatory Considerations
For TREM3 clinical development:
Preclinical Safety: Toxicology assessment
Dosing Optimization: Phase I design
Patient Selection: Biomarker-driven
Endpoint Selection: Clinical outcomesEconomic Analysis
TREM3 therapy development:
- Drug discovery costs
- Clinical trial investments
- Manufacturing expenses
- Market potential
Global Health Impact
TREM3-targeted interventions:
- Infectious disease treatment
- Autoimmune disease management
- Cancer immunotherapy
- Inflammatory conditions
Research Infrastructure
Required resources:
- Antibody development facilities
- Mouse model systems
- Patient sample collections
- Clinical trial networks
Training Needs
Expertise required:
Immunology: Myeloid cell biology
Therapeutics: Antibody development
Clinical: Trial design and execution
Manufacturing: GMP productionFunding Landscape
Support for TREM3 research:
- Pharmaceutical industry investment
- NIH grant funding
- Foundation support
- Academic partnerships
Competitive Landscape
TREM3 versus other immune targets:
| Target | Function | Development Stage | Market Potential |
|--------|----------|-------------------|------------------|
| TREM3 | Immune activation | Preclinical | Moderate |
| TREM2 | Phagocytosis | Clinical | High |
| TREM1 | Inflammation | Clinical | Moderate |
| SIRPα | Immune checkpoint | Clinical | High |
Future Directions
Emerging research areas:
Structural Biology: TREM3 structure determination
Ligand Discovery: Natural ligand identification
Clinical Translation: First-in-human studies
Companion Diagnostics: Patient selectionConclusion
TREM3 represents an emerging immunotherapeutic target with potential applications in infectious disease, autoimmunity, and cancer. While significantly less studied than TREM2, TREM3 offers unique perspectives on myeloid cell activation and inflammatory responses. Continued research will clarify its precise roles and enable development of TREM3-targeted interventions.